Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
BackgroundThe prevalence of patients positive for muscle-specific kinase antibody (hereafter, MuSK-Ab) accounts for 5–8% of all myasthenia gravis (MG) cases. Currently, efgartigimod has shown good therapeutic effects in MUSK-Ab-positive MG patients in a phase III clinical trial. However, phase III c...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1486659/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|